Market closed
Qualigen Therapeutics Inc./$QLGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Ticker
$QLGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
4
Website
QLGN Metrics
BasicAdvanced
$2.3M
-
-$41.53
0.14
-
Price and volume
Market cap
$2.3M
Beta
0.14
52-week high
$4.02
52-week low
$2.85
Average daily volume
86K
Financial strength
Current ratio
0.519
Quick ratio
0.379
Total debt to equity
-66.993
Interest coverage (TTM)
-6.42%
Management effectiveness
Return on assets (TTM)
-126.39%
Return on equity (TTM)
411.01%
Valuation
Price to book
-0.79
Price to tangible book (TTM)
-0.79
Price to free cash flow (TTM)
-0.061
Growth
Earnings per share change (TTM)
-76.92%
3-year earnings per share growth (CAGR)
-29.86%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Qualigen Therapeutics Inc. stock?
Qualigen Therapeutics Inc. (QLGN) has a market cap of $2.3M as of April 16, 2025.
What is the P/E ratio for Qualigen Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Qualigen Therapeutics Inc. (QLGN) stock is 0 as of April 16, 2025.
Does Qualigen Therapeutics Inc. stock pay dividends?
No, Qualigen Therapeutics Inc. (QLGN) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Qualigen Therapeutics Inc. dividend payment date?
Qualigen Therapeutics Inc. (QLGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Qualigen Therapeutics Inc.?
Qualigen Therapeutics Inc. (QLGN) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.